Vivek Subbiah: Great JAMA weekend read on highlights from ASCO24

Vivek Subbiah shared on LinkedIn:

“Happy Friday, World! Hot off the press – published in JAMA!

Excited to chat with the amazing Dr. Mary (Nora) Disis, Editor in Chief of JAMA Oncology, Deputy Editor at JAMA and terrific Dr. Monica Morrow, Associate Editor at JAMA Oncology, about the exciting cancer research at ASCO24.

Great JAMA weekend read – Medical News and Perspectives! Link here.”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.